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Case Report
Abstract
Angiosarcoma is a rare malignancy of vascular origin. It can affect any part of the body, head and neck region being probably
the most common site of diagnosis. We present here a case of Angiosarcoma of face in a 67-year-old elderly gentleman who was
treated with RapidArc – volumetric modulated arc therapy (VMAT) for recurrence after surgery, radiotherapy and chemother-
apy. As an alternative to Electron Beam Therapy, RapidArc with skin bolus can be considered for large complex shaped targets




Angiosarcoma is a rare malignancy of vascular origin and
accounts for approximately 2% of soft tissue sarcomas. It can
affect any part of the body, one third being cutaneous and one
fourth being of soft tissue origin. These tumours arise from
vascular endothelium, show multifocality and can spread to
lymph nodes and distant sites. The peak age of incidence
appears to be seventh decade and men are affected more than
women. Causes of angiosarcoma include therapeutic radia-
tion, exposure to vinyl chloride and chronic lymphedema
(Stewart-Treves syndrome).1 Head and neck region is proba-
bly the most common site of diagnosis and there is a predi-
lection for sun exposed skin of scalp in older individuals.
Head and neck angiosarcoma morphologic appearance is
somewhat distinct from other locations by its common asso-
ciation with a heavy lymphocytic infiltrate that can obscure
its findings.2 Angiosarcoma expresses the typical vascular
markers: CD34, CD31, Fli-1 and ERG.3, 4
Standard treatment for angiosarcoma includes surgical exci-
sion with clear margins followed by local radiotherapy with
or without systemic chemotherapy.
Case presentation
A 67-year-old gentleman with no medical co-morbidities,
presented to us in September 2012 with 3 months history of
ulcerative growth over right ala of nose, which started as a
small nodule which eventually grew and ulcerated with
bloody discharge. On clinical examination, there was evi-
dence of a nodular-ulcerated lesion measuring 4 × 3 cm over
the right ala of the nose with uneven surface, irregular diffuse
margins and indurated erythematous skin over the right
cheek adjacent to the lesion.
There was no evidence of palpable cervical lymphadenopa-
thy. Skin biopsy showed evidence of poorly differentiated
carcinoma. Patient underwent wide local excision with flap
reconstruction.
The post-operative histopathology and Immunohistochemis-
try IHC study was suggestive of angiosarcoma with positive
resected margins. Patient received post-operative radiation
therapy to a dose of 60 Gy in 30 fractions with intensity
modulated radio therapy IMRT in October-November, 2012.
Subsequently, he was started on adjuvant chemotherapy with
inj. Paclitaxel. Patient developed local recurrence character-
ized by erythematous-bullous lesion over the right zygomatic
region (Figure 1) in the month of July 2013 immediately after
completing 5 cycles of adjuvant chemotherapy.
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FIG. 1: Multiple cutaneous biopsies were taken to map the micro-
scopic spread of the disease. Right zygomatic region shows recurrent
lesion.
Imaging findings
Preoperative whole-body positron emission tomography
(PET-CT) scan revealed evidence of 3 × 2 cm metabolically
active irregular soft tissue mass in right nasal ala with SUV
Max of 10.3 with no evidence of any nodal or distant metas-
tasis. Whole-body PET CT performed 3 months post radiation
therapy showed no evidence of any locoregional recurrence
or distant metastasis. PET CT performed 7 months post radi-
ation therapy (Figure 2) revealed evidence of locoregional
recurrence characterized by:
1. Intense FDG uptake with Standardized Uptake
Value (SUV) Max of 12.7 in a plaque like area in the
skin and subcutaneous tissue over the right maxil-
lary and zygomatic region involving right lower
eyelid and right medial canthus.
2. Another intense FDG uptake with SUV Max of 11
in a similar area of skin thickening on the left side of
the face involving left medial canthus and upper
zygomatic region.
3. Another focus of intense FDG uptake with SUV
Max of 10 in the area of skin thickening in the right
buccal region.
4. Focal increased FDG uptake with SUV Max of 7 in
the nasal bridge just above the level tip of nose.
5. No evidence of metabolically active disease else-
where to suggest distant metastasis.
FIG. 2: PET CT scan axial images showing metabolically active re-
current lesions.
Biopsy from the skin confirmed it as recurrent angiosarcoma.
Second surgery was deferred by the head and neck surgeon in
view of his elderly age and difficulty in achieving negative
margins considering the local extent and multifocality of the
disease on PET-CT. Since the disease was chemotherapy
refractory, he was referred to us for re-irradiation as the only
available option. To map the local extent of the disease, he
underwent multiple cutaneous biopsies 4-5 cm from the
periphery of documented recurrent lesions (Figure 1). All the
seven biopsy specimens were negative for malignancy.
We simulated this patient on a 16-slice PET-CT simulator.
Patient was immobilized using a thermoplastic mask in neu-
tral head position. CT images were acquired in 1.25 mm slice
thickness from vertex to mid chest. PET-CT fusion was per-
formed using Eclipse version 10.0 software. Gross tumor
volume (GTV) included FDG avid PET positive disease and
clinical target volume (CTV) included GTV + 3 cm margin to
incorporate microscopic disease. CTV was cropped from the
adjacent organs at risk (OARs). Planning target volume (PTV)
included CTV + 0.5 cm margin for setup errors. Prescription
dose was 60 Gy in 30 fractions to the PTV.
Discussion
For superficial tumours of skin and subcutaneous tissue,
electron beam therapy is an ideal modality of radiation
therapy. One of the basic requirements for electron beam
therapy is presence of relatively flat or symmetric treatment
area in order to reduce chances of excessive dose inhomoge-
neity. Sharp surface irregularities where the electron beam
may be incident tangentially give rise to a complex dose dis-
tribution with localized over-dose (hot-spot) and under-dose
(cold-spot).5 In our case, the PTV included almost entire face
which made it extremely difficult to be treated with electron
beam, considering the surface irregularity and tissue inho-
mogeneity. Hence, we decided to treat this patient with
RapidArc (Volumetric Modulated Arc Therapy-VMAT) 6, 7, 8
using 0.5 centimetres wax bolus over the thermoplastic cast
(Figure 3) to bring the prescribed isodose up to the level of
skin surface. Zacarias et al.9 used VMAT for superficial tar-
gets and could achieve improved dose uniformity close to
skin surface. Treatment planning was done using two
co-planar arcs with 360 degree rotation. 0.5 cm tissue equiv-
alent bolus over the PTV was used for planning purpose
(Figure 4A−E). In-vivo dose measurement was done to con-
firm the superficial dose build-up. Figure 5 shows brisk cu-
taneous reaction during the course of treatment. Dose ho-
mogeneity index [Imax/Iref] 10, 11 was 1.09 and conformity index
[Vref/VT]11 was 1.04. 97% of the PTV received 100% of the
prescribed dose.
FIG. 3: Thermoplastic mask with 0.5 cm custom wax bolus for surface
dose build-up.
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FIG. 4: A: Simulation CT showing PTV contour (red), CTV (cyan), GTV (magenta) and custom bolus over the skin (grey); B: PET image showing
FDG avid lesion over the right, left zygomatic region and nasal bridge; C: PET-Planning CT fusion, D: Dose distribution in color wash showing
PTV coverage and dose build-up on the skin surface with custom bolus; E: 3-dimentional rooms-eye-view of patient and custom bolus.
FIG. 5: Clinical photographs during the course of treatment showing brisk cutaneous reaction due to adequate cutaneous dose build-up.
A: 2nd week; B: 3rd week; C: 4th week; D: 5th week; and E: 6th week of radiotherapy.
Conclusion
Radiotherapy for large cutaneous angiosarcoma of face is
challenging considering the surface irregularity and tissue
inhomogeneity. As an alternative to electron beam therapy,
RapidArc (VMAT) can be considered for such cases using
tissue equivalent bolus for cutaneous build-up of the dose.
RapidArc (VMAT) can achieve reasonable dose homogeneity
and conformity with adequate target coverage.
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